Cancer is the second leading cause of death in the United States.
I
n the United States, the lifetime risk for cancer is 43.3% in men and 37.8% in women (1) , and cancer is the second leading cause of death (2) . In 2016, there will be an estimated 1 685 210 new cancer cases and 595 690 cancer deaths (3) . As such, primary prevention of cancer is an important public health objective. Chemoprevention (4) of cancer with aspirin is of particular interest as a primary prevention strategy.
We found no established groups that currently recommend aspirin use for prevention of cancer in general or for specific cancer types (5-9), except for consideration in certain individuals at high risk for colorectal cancer (CRC), such as persons with Lynch syndrome (10) . Consistent with the U.S. Preventive Services Task Force's (USPSTF's) 2007 findings (11) , the American Cancer Society recommends against aspirin use for CRC prevention in the general population (3) . In updating its recommendation, the USPSTF considered cancer prevention, including CRC, as contributing to an assessment of the net benefits and harms of aspirin use in a population eligible for the primary prevention of cardiovascular disease (CVD). This article summarizes 2 concurrent systematic reviews that addressed the effects of aspirin use on total cancer incidence and mortality and on CRC incidence and mortality (12, 13) . These reviews were used in conjunction with systematic reviews on CVD events (14) and harms associated with aspirin use (13) and a decision model (15) to update USPSTF recommendations on aspirin use. CRC report (12) . The full reports for the USPSTF also describe our methods in detail (12, 13) .
Data Sources and Searches
We conducted separate literature searches for total cancer and CRC but used similar methods. For total cancer, we based our review on 2 individual-patient data (IPD) meta-analyses of randomized, controlled trials (RCTs) published through 2010 (18) and 2011 (19) that examined the effects of daily aspirin on cancer incidence and/or mortality. We supplemented these reviews through a comprehensive bridge search of PubMed, MEDLINE, and the Cochrane Central Register of Controlled Trials (1 January 2011 to 6 January 2015). We also reviewed bibliographies of previous and concurrent USPSTF reviews and other recent relevant reviews (12, 14, 20, 21) . For CRC, we assessed all studies from the previous USPSTF review (20) , performed a comprehensive search using the databases listed earlier from 1 January 2004 to 6 January 2015, and examined reference lists of relevant literature.
Study Selection

Total Cancer
Pairs of investigators independently reviewed titles, abstracts, and full-text articles of studies against prespecified criteria (12, 13) . We included RCTs and controlled clinical trials conducted in adults (aged ≥40 years) that compared regular oral aspirin use (≥75 mg at least every other day) versus placebo or no treatment for at least 1 year for any indication. We excluded randomized groups that included other antithrombotic or chemopreventive agents and trials in adults with a personal history of cancer or a high prevalence of familial cancer syndromes (such as Lynch syndrome). We limited the review to fair-and good-quality trials (see Data Extraction and Quality Assessment) published in English and conducted in countries with a "very high" Human Development Index in 2013 (22) . We included 1 IPD meta-analysis that included studies of less than 1 year of aspirin use because it reported outcomes (timeto-event and individual cancer types) not available from reports of individual trials (19) .
CRC
Inclusion and exclusion criteria were similar to those in the total cancer review with a few exceptions: We included prospective cohort studies in the full report (not reported here because they did not alter conclusions [12] ), we did not exclude studies of patients with prior cancer types other than CRC, we did not exclude randomization groups that included other antithrombotic agents, and we did not restrict by country.
Data Extraction and Quality Assessment
Pairs of investigators independently assessed the quality of included studies by using USPSTF criteria (23) and supplemented the quality criteria for systematic reviews with AMSTAR (A Measurement Tool to Assess Systematic Reviews) (24) . Good-quality studies met the majority of criteria. Fair-quality studies did not meet or did not clearly meet all criteria for a good-quality study.
We excluded outcomes from 20 articles (25-44) from the total cancer review and none from the CRC review due to poor quality (>40% attrition, >10% difference in attrition between groups, other fatal flaws, or multiple minor flaws or missing information important enough to limit confidence in the validity of results). One investigator abstracted data from included studies, and another checked the data for accuracy.
Data Synthesis and Analysis
For total cancer, we focused on results from CVD primary prevention trials included in our companion reports (13, 14) for consistency, but we included a broader set of studies in sensitivity analyses. For CRC, we analyzed CVD primary and secondary prevention studies together; we present results stratified by follow-up period after initiation of aspirin therapy (early-onset: 0 to 10 years; late-onset: 10 to 20 years; longterm: 0 to ≥20 years) because of apparent large differences in effect by time since initiation. We planned analyses of dose, frequency, duration, formulation, and recency of use a priori (45) and selected cut points empirically. For consistency with the CVD prevention review, we classified aspirin use by dose (high-dose: >325 mg/d; low-dose: ≤325 mg/d; very-low-dose: ≤100 mg/d [14] ). If duration was not reported, we used mean in-trial length of follow-up to represent the intended duration of aspirin use, and the term "duration" in the text refers to this concept.
We used the Mantel-Haenszel fixed-effects model to estimate effects when combining studies (46). We explored prespecified subgroups of interest, including age, sex, race/ethnicity, baseline cancer risk (family history and other cancer risk factors), and diabetes status. We were unable to pool results because of the limited number of contributing studies. We used Stata 12.0 (StataCorp) for all statistical analyses.
Role of the Funding Source
Agency for Healthcare Research and Quality (AHRQ) staff provided oversight for the project. Liaisons from the USPSTF helped to resolve issues around the scope of the review but were not involved in the conduct of the review.
RESULTS
Description of Included Trials
We identified 20 fair-or good-quality RCTs (47-66) and 4 IPD meta-analyses (18, 19, 67, 68) of aspirin use that provided cancer outcomes (Tables 1 and 2) . Nine of the RCTs were of daily aspirin use in CVD primary prevention populations (47-55), 1 of which (47) was not included in our companion reports. Two were of alternate-day aspirin use for primary CVD and cancer prevention (56, 57), and 9 were of daily aspirin use for CVD secondary prevention (58 -66). Persistence of aspirin use during trials was generally high (≥85%) in the first year of the studies before decreasing to 50% to 83% after 3 to 5 years, with substantial variability across studies (12) . Inclusion and exclusion criteria used in the 4 included meta-analyses are compared in Table 2 . Figure 1 . Briefly, they focus on the association between aspirin and 1) cancer-related and all-cause mortality, 2) total cancer incidence, 3) colorectal cancer mortality, and 4) colorectal cancer incidence. † Factorial design. ‡ Median. § Cancer also specified as a primary outcome. ͉͉ Total number randomly assigned when warfarin groups included. ¶ Targeted diabetic retinopathy but excluded patients with coronary artery disease. The trial randomly assigned 475 patients to 3 groups; the group randomly assigned to aspirin plus dipyridamole (n = 161) was excluded from our analysis.
For CRC, most outcomes came from 3 IPD metaanalyses by Rothwell and colleagues (18, 67, 68) of daily aspirin use in trials of either primary or secondary CVD prevention ( Table 2 ). Rothwell and colleagues selected trials of daily aspirin use on the basis of availability of follow-up data, scheduled duration of aspirin use, and population size, with specific criteria varying across the analyses. More than three quarters of trial participants were male. Where possible, Rothwell and colleagues linked study populations with national registries to obtain CRC incidence and mortality data. Posttrial persistence information was not available, but approximately 50% to 75% of participants continued to use aspirin 5 years into follow-up. Results from the WHS (Women's Health Study) (56, 69) and the PHS (Physicians' Health Study) (70)-studies of alternate-day aspirin use in U.S. health care workers, which were not included in Rothwell and colleagues' analyses-were reported in separate publications ( Table 1) .
Total Cancer Mortality
Ten CVD primary prevention trials included in our companion report (13) Table) . In another meta-analysis of primary and secondary prevention trials testing daily aspirin use for more than 90 days among 69 224 participants (19) , a priori-stratified analysis showed no differences in cancer deaths until at least 5 years, except for an effect during the first 3 years among trials of high-dose aspirin. Various analyses of deaths from different cancer types in both metaanalyses (18, 19) suggested reductions in solid gastrointestinal cancer and adenocarcinomas after at least 5 years of aspirin use but were limited by relatively few site-specific cancer deaths and excluded large trials of alternate-day aspirin use (56, 57).
Among 39 876 women in WHS, the cumulative risk for cancer death 17.5 years after randomization (approximately 4%) was similar between groups (HR, 0.97 [CI, 0.88 to 1.07]) (69) . In an IPD meta-analysis (18) of 12 659 participants (95% male) in 3 primary or secondary prevention trials (52, 54, 64) with median durations of aspirin use of 4 to 6.8 years, longer treatment duration was statistically significantly related to decreased mortality risk 20 years after randomization for nonhematologic cancer (P for interaction = 0.01), with no benefit for less than 5 years of intended use and the greatest benefit with at least 7.5 years of use. Only 1 of these trials (a secondary prevention trial) included women (64) . Among the 83% of participants with at least 5 years of intended treatment, those allocated to aspirin had 22% fewer cancer deaths than control participants from 0 to 20 years (HR, 0.78 [CI, 0.70 to 0.87]). No data were reported to assess whether groups remained comparable at baseline after exclusion of participants (17%) who had less than 5 years of intended treatment. Specific cancer mortality findings were limited by power and methodological and clinical heterogeneity; however, exploratory analyses suggested that minimum treatment duration (5 to 10 years) and time until mortality reduction (5 to 20 years) may vary across cancer types.
Total Cancer Incidence
Among 6 primary prevention trials (Table 1) WHS and PHS are alternate-day dose studies (100 mg every other day and 325 mg every other day, respectively); TPT data do not include the warfarin groups. We used data from the individual-patient data meta-analysis (if data were not reported in the study or if they differed from those reported in the study) as follows: for BMD and AAA, data from Rothwell and colleagues (18) ; for PPP and HOT, data from Rothwell and colleagues (19) ; and for PHS, data from Seshasai and colleagues (71) available at www.annals.org). We observed a marginally statistically significant reduction in cancer incidence only when we restricted our analysis to trials of daily aspirin use with a median intended duration of at least 4 years and also included secondary prevention studies (66) (4 trials; n = 11 800; RR, 0.86 [CI, 0.74 to 0.99]).
In a time-to-event IPD meta-analysis (19) of 6 trials of daily low-dose aspirin in primary prevention populations (48, 50 -53, 55), cancer incidence (with fatal and nonfatal cancer cases combined) was reduced, with borderline statistical significance (HR, 0.88 [CI, 0.80 to 0.98]), beginning 3 to 4 years after randomization, with statistically significantly greater effects as follow-up duration increased beyond 3 years (P for interaction with duration = 0.04) (19) . We found no statistically significant effect of aspirin on cancer incidence among this set of trials after a priori exclusion of studies reporting fatal cancer only (53) and warfarin co-treatment (52) (RR, 0.92 [CI, 0.82 to 1.02]) (48, 50, 51, 55).
Overall cancer incidence (5071 cases, excluding nonmelanoma skin cancer) was not reduced among aspirin users in age-adjusted analyses (HR, 0.97 [CI, 0.92 to 1.03]) after a median of 17.5 years in WHS (69), regardless of whether data were analyzed over the entire follow-up or were stratified by within-trial or posttrial period. Cancer incidence was not reduced at any specific non-CRC site (including a priori secondary study outcomes of breast or lung cancer) cumulatively, during the trial, or after the trial. However, most other cancer types were relatively uncommon, and analyses therefore lacked power. Even when grouped by site, only gastrointestinal cancer incidence was reduced in the posttrial follow-up period, whereas incidence of urinary tract, respiratory tract, reproductive tract, and hematologic cancer was unaffected.
CRC Mortality
Rothwell and colleagues reported data on longterm CRC mortality (median follow-up, 18.3 years) using pooled data from 2 primary (52, 54) and 2 secondary (61, 64) CVD prevention trials (n = 14 033) (68) . Long-term cumulative risk for CRC death (0 to ≥20 years) was reduced among patients assigned to take 75 to 1200 mg of aspirin per day for at least 1 year (median intended duration, ≥2. (18) .
In another IPD meta-analysis (18), Rothwell and colleagues used data from 6 trials of primary or secondary CVD prevention with a median intended duration of at least 4 years (50, 52-55, 64) (n = 19 824) to examine the in-trial effect of 75 to 1200 mg of aspirin per day ( Table  2) . They did not report a statistically significant effect on CRC mortality during the first 5 years after randomization (HR, 0.78 [CI, 0.39 to 1.56]), but they did find a borderline statistically significant effect after at least 5 years of in-trial follow-up (HR, 0.41 [CI, 0.17 to 1.00]) (18) .
Of the 2 CVD primary prevention studies that also had cancer as an a priori outcome, 1 (PHS) did not report on CRC mortality. The WHS (n = 39 876) found no effect on CRC mortality with very-low-dose aspirin taken on alternate days during the first 10 years of follow-up (data not shown) but did not report on late or long-term risk for CRC death (56).
Evidence on dose was limited to 4 trials of daily aspirin use for primary (52, 54) or secondary (61, 64) prevention of CVD (n = 14 033). Doses ranged from 75 to 1200 mg/d. All included trials randomly assigned patients to daily aspirin use and could not, therefore, compare daily versus alternate-day use. Analyses did not clearly suggest an effect of the dose (12) . An IPD meta-analysis (68) of the same trials reported a statisti- 
CRC Incidence
Data on CRC incidence came from 2 IPD metaanalyses by Rothwell and colleagues (67, 68) and separate reports from the PHS (70) and the WHS (69). None of the trials directly compared aspirin doses. However, an IPD meta-analysis that conducted preplanned analyses of aspirin dose observed similar effects on CRC incidence overall and when the analyses were restricted to patients randomly assigned to 75 or 300 mg/d (results not shown) (68) . No trial directly compared the effect of daily versus alternate-day aspirin use on CRC incidence. We found few data on the effect of treatment duration (67, 68) ; our findings are described in detail in the full report (12) . Briefly, the point estimates were similar for analyses that included all scheduled durations of use and those that were restricted to persons with scheduled durations of at least 5 years. These findings indirectly suggested no difference in effect by duration of use. However, in 1 of the included RCTs, scheduled duration varied from 1 to 7 years and the effect of aspirin was greater with longer scheduled durations of use (P for interaction = 0.009 with duration as a continuous variable and 0.004 with duration dichotomized at 5 years) (67). 
Subgroup Differences
Limited data did not clearly suggest variation in the effect of aspirin use on total cancer or CRC mortality or incidence by age, sex, or other patient characteristics. Details are described in the full reports (12, 13) .
DISCUSSION
On the basis of 10 CVD primary prevention trials, we found no statistically significant reduction in total cancer mortality (RR, 0.96 [CI, 0.87 to 1.06]). Others have found no established protective effect for aspirin on total cancer mortality in the CVD primary prevention population in similar analyses (71) . In 4 trials in primary and secondary CVD prevention populations, we found that aspirin reduced CRC mortality over approximately 20 years of follow-up (RR, 0.67 [CI, 0.52 to 0.86]). Although the estimate lacked precision, aspirin appeared to reduce CRC incidence after 5 years of follow-up. A large U.S. trial of women taking very-low-dose, alternate-day aspirin for primary prevention of CVD and cancer reported no total cancer mortality effect after 10.1 years of treatment and 17.5 years of follow-up, but the trial did not report results for CRC mortality separately.
Effects of aspirin therapy on total cancer incidence within 10 years of initiation were generally small (2% reduction) and not statistically significant, even when analyses were restricted to studies with daily dosing and median scheduled treatment of at least 4 years. Only the analysis that included both primary and secondary CVD prevention populations assigned to daily aspirin (75 to 500 mg) for at least 4 years showed a statistically significant reduction in cancer incidence after 4.2 to 8.2 years. Longer-term follow-up data were available on CRC incidence in 3 studies, including WHS, and suggested a 40% reduction in risk approximately 10 to 19 years after randomization. A pooled analysis of these studies plus one other showed no effect during the first 10 years after randomization. Over a 20-year period, the cumulative effect was an approximately 20% reduction in CRC incidence in persons assigned to take aspirin; however, the upper CI limits were near 1.0 in both Rothwell and colleagues' analysis and the WHS analysis. Follow-up in PHS was limited to a mean of 12 years and therefore could not contribute to analyses of late and long-term effects. Cohort studies presented some evidence for reduced CRC risk with increases in the number of aspirin tablets per week and duration of use but added little information on timing of effect or dose; results of these studies are presented in more detail in the full report (12) .
Data were too limited to generate consistent or definitive results for any specific type of cancer beyond CRC. Nonetheless, exploratory analyses suggested that adenocarcinomas and/or solid cancer of gastrointestinal origin may respond to aspirin chemoprevention. Additional data from applicable populations using lowdose aspirin will likely clarify and extend these findings.
Our findings on aspirin's effect on total cancer differed from those in a widely reported meta-analysis that found a statistically significant 21% reduction (CI, 8% to 32%) in cancer mortality (18) . However, this metaanalysis used a different set of studies from the ones in our analysis of CVD primary prevention trials; it included trials of CVD secondary prevention but restricted analyses to daily aspirin use for a median treatment duration of at least 4 years (18) . Similarly, other analyses of cancer outcomes from the same group have often relied on subsets of trials that could provide longer-term follow-up (13) . However, these analyses also differ in terms of populations and interventions from the body of CVD primary prevention trials, which may explain differences from our results.
Cuzick and colleagues used a modeling approach to conclude that the benefits of initiating therapy with at least 5 years of 75 to 325 mg of aspirin per day at ages 50 to 65 years outweighed the risks (72) . Model inputs (RRs) were derived from recent reviews of RCTs and observational studies. The comparability of our 2 reviews is limited given that Cuzick and colleagues did not present an overall estimate for total cancer and we do not present estimates for individual cancer types other than CRC because they were not frequently reported. Relative risk estimates for aspirin use and CRC incidence and mortality differ from ours in part because Cuzick and colleagues focused on daily use (that is, they did not include WHS or PHS) and included observational studies.
In general, our findings on aspirin use and CRC incidence and mortality are similar to those previously reported (73) . However, in an article that did not meet the inclusion criteria for our CRC review, Rothwell and colleagues reported that aspirin therapy may reduce CRC mortality within 10 years of initiation (19) . Reviews of cohort studies have generally reported stronger protective associations between aspirin and CRC incidence than RCTs (74 -76) .
Several limitations in the available data affected our review. Most data were collected post hoc as part of follow-up studies of CVD trials (18, 19, 67, 68) . Clinical and methodological heterogeneity across studies complicated the interpretation of subsets of trials with the longer-term data needed to study aspirin's effect on cancer. Limited data were available to assess cancerspecific effects (18, 56) and subgroup differences. Data on cancer risk factors, such as family history, were generally unavailable. We also could not address questions about how long the effects of aspirin may continue after the end of treatment.
Because aspirin is one of the most extensively studied medications, establishing appropriate exclusion criteria was essential to managing the scope of this review. Thus, we focused on RCTs and IPD meta-analyses to enhance validity. In addition, for total cancer outcomes, we focused on CVD primary prevention trials to ensure applicability to the clinical context of primary prevention of both CVD and cancer. Observational studies may provide information on subgroup effects once efficacy is established, particularly for individual cancer types. We considered prospective cohort studies in our review of aspirin use and CRC incidence and mortality and, despite imprecision of exposure data, findings were generally consistent with trial data (12) .
Longer-term follow-up from trials could provide important information on the effects of aspirin on cancerspecific sites and cancer overall, particularly with respect to the size and timing of chemopreventive benefits, dose-response relationships, effect of duration of use, and differences across patient subgroups. The primary data for aspirin's effects on a range of health outcomes have not changed substantially over the past several years, but the field is poised to provide additional data in the near future. Several large trials are in progress (77-80), and future syntheses of existing and emerging evidence should be forthcoming from the NoVA (Non-Vascular outcomes on Aspirin) Collaboration, which aims to collate all data from previous and ongoing trials of aspirin to provide data on short-and long-term effects that are as complete as possible (81). Observational studies or trials focused on subgroups defined by genotype, lifestyle factors, or biomarkers may also provide important data to understand which subgroups are more or less likely to benefit from aspirin use (82-86).
In conclusion, in CVD primary prevention populations taking low-dose aspirin for chemoprevention, a beneficial effect on total cancer mortality or incidence is not clearly established. Data are limited for effects on specific cancer types, except perhaps CRC. Evidence from primary and secondary prevention studies suggests that aspirin therapy reduces the risk for CRC incidence and perhaps mortality, with an apparent preventive effect beginning approximately 10 years after initiation. 
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